Leukocytes infiltration correlates intratumoral microvessel density and influence overall and late-phase disease-free survival in hepatocellular carcinoma

Yuan Yang, MDa, Ning Fu, MDb, Haiqing Wang, MDC, Jingcheng Hao, MDa,b,*

Abstract

Hepatocellular carcinoma (HCC) is a severe type of primary liver cancer with high postoperative recurrence. The prognosis predictability of tumor-infiltrating leukocytes (TILs) for patients who underwent HCC resection has been widely reported. However, limited information is available about TIL trafficking, which is also crucial for HCC patients.

We included tumor tissue samples and clinical data from 89 HCC patients in this study and performed immunohistochemistry for CD3, CD6, FoxP3, and CD31. TILs were measured using an algorithm for quantification of tumor immune stroma (QTIS). Intratumoral microvessels were counted using Weidner’s method. We first examined correlations among them and analyzed their relationships with clinical and survival data.

Intratumoral microvessel density (iMVD) was significantly correlated with infiltration of CD3+ (r = 0.338, P = 0.001) and CD8+ (r = 0.320, P = 0.002) cells, but not FoxP3+ (r = 0.153, P = 0.152) cells. After multivariate analysis, higher infiltration of CD3+ (P = 0.038) independently showed significant predictability on better overall survival after resection of HCC. Although no influence of CD3+ (P = 0.386) and CD8+ (P = 0.648) cells were found on general disease-free survival, infiltration of CD3+ (P = 0.012), tumor size (P = 0.032) and albumin (P = 0.007) cells independently predicted late-phase disease-free survival. No significant relationships regarding iMVD, and infiltration of FoxP3+ cells with overall and disease-free survival were found.

Our data suggest that increased iMVD could enrich tumor-infiltrating CD3+ cells. Infiltrated CD3+ cells could help to better predict both the overall and late-phase disease-free survival after resection of HCC.

Abbreviations: AFP = serum alpha-fetoprotein, ALT = alanine transaminase, BCLC = barcelona clinic liver cancer, HCC = hepatocellular carcinoma, HPF = high power field, iMVD = intratumoral microvessel density, IQR = interquartile range, QTIS = quantification of the tumor immune stroma, TIL = tumor-infiltrating leukocyte, Tregs = regulatory T cells.

Keywords: hepatectomy, hepatocellular carcinoma, intratumoral microvessel density, prognosis, tumor-infiltrating leukocytes

1. Introduction

Hepatocellular carcinoma (HCC) is a dominant type of liver malignancy. It is also the second principal cause of cancer-related fatality worldwide. [1] Hepatectomy is the most efficient curative treatment for HCC. Despite the unceasing improvement of resection techniques, postoperative recurrence rate can reach up to 70% in 5 years, and this recurrence leads to a high rate of death in HCC patients. [2] Therefore, it is essential to improve strategies to predict and prevent postoperative HCC recurrence.

Immunology has been shown to play a significant role in malignancy development. [3] Changes in the immune system have been investigated in HCC for many years. [3] In previous studies, tumor-infiltrating leukocytes (TILs), especially those infiltrating CD3+ and CD8+ cells, have been extensively reported as predictors for survival in numerous human solid malignant tumors. [4,5] Moreover, the predictabilities of these infiltrating leukocytes are suggested to be better than that of conventional clinical staging systems. [6]

Not only does the type and amount of TILs, but also the trafficking needs to be deliberated. Neovascularized arteries mainly supply to the HCCs. [7] Neovascularization is necessary for cancer development by delivering nutrition and oxygen. However, it could also possibly enhance leukocyte infiltration, which in theory is reliant on intratumoral blood vessels. Furthermore, the strong correlations between endothelial venules
and leukocyte infiltration have been proven in many human solid malignancies, such as melanomas, breast, ovarian, colon, and lung carcinomas. In particular, these high endothelial venules conferred better survival in invasive breast cancer. Additionally, animal studies have shown that regulatory T cells (Tregs), which could promote tumor progression by their immunosuppressive abilities, could also stimulate neovascularization. However, few studies have provided similar information regarding HCC.

In the present study, we investigated the expression of total T cells, cytotoxic T cells, regulatory T cells, and intratumoral microvessel density (iMVD) in resected HCC tissues, the potential correlations among them, and their relationships to clinical data.

2. Material & methods

2.1. Patients and clinical data

We collected tumor tissues samples from 89 curatively resected HCC patients from October 2013 to November 2017. The diagnoses of all patients were in accordance with the guidelines for diagnosis and treatment of primary liver cancer in China. Clinical diagnoses of all cases were confirmed histologically after resection. All tumor samples were anonymously coded during the experimental procedure. This study was approved by the institutional review board of Chendgu Medical College, China. Data collection and experiments were carried out in accordance with the ethical guidelines of the Declaration of Helsinki. Informed consent for data and tissue collection from all study subjects (if subjects were under 18 years of age, from corresponding legal guardians) was obtained at admission.

We collected the following epidemiological and clinical data from medical records in our database for statistics: gender, age at operation, history of hepatitis, presence of cirrhosis, tumor size and number in preoperative imaging, microvascular and macrovascular invasion, Barcelona clinic liver cancer (BCLC) staging, Milan staging, routine laboratory examination results including white blood cell count, hemoglobin, platelet count, alanine transaminase (ALT), aspartate transaminase, bilirubin, albumin, and serum alpha-fetoprotein (AFP) levels.

2.2. Immunohistochemical staining

We performed immunohistochemical staining as described previously. Four-micrometer sections of paraffin blocks were prepared for staining. Dewaxing and hydration were performed with xylene, ethanol, and distilled water. Antigens were retrieved using citrate buffer (pH 6.0) or EDTA solution (pH 8.0). Following incubation with antibodies for CD3 (ab5690, Abcam Plc.), CD8 (ab4055, Abcam Plc.), FoxP3 (ab4055, Abcam Plc.), and CD31 (ab28364, Abcam Plc.), incubation with secondary antibodies was carried out. 3,3-Diaminobenzidine method was used for staining. Counterpart staining was performed using Hemalaun. Negative and isotype controls were used as appropriate.

2.3. Analysis of immunohistochemical staining

2.3.1. Quantification of tumor-infiltrating leukocytes. TILs were quantified using an algorithm for quantification of tumor immune stroma (QTIS). Hotspots were defined as areas with the highest infiltration density and were chosen under a low-power magnification (40×). In accordance with the QTIS algorithm, we analyzed the mean amount of the three hotspots. The images were captured under high-power magnification (Nikon Eclipse Ci with Nikon Plan, 200×). The number of positive cells per image was counted using ImageJ software (version 1.52p, National Institutes of Health; Bethesda, MD, USA) with threshold adjustment for further analysis.

2.3.2. Quantification of intratumoral vessels. To measure intratumoral vessels, we adopted the method published by Weidner in 1995. This method is also a quantification strategy that is based on “hotspot-choosing,” which is similar to the QTISs we used for TILs. We scanned the slides under a low-power magnification (40×) and selected those regions with the highest number of intratumoral vessels as hotspots. We also analyzed the mean amount of 3 hotspots that were captured under high-power magnification (200×). In accordance with Weidner’s method, we counted the number of vessels instead of stained cells.

2.4. Statistical analysis

The distribution of continuous data was inspected by Shapiro–Wilk test. Continuous numbers were presented as mean±SD (normal distribution) or median (interquartile range [IQR]) (skewed distribution), and compared using an independent t-test (normal distribution) or Mann–Whitney U test (normal distribution). We compared contingency data using χ²-test or Fisher exact test, and assessed the correlation by calculating Pearson’s r values. For survival analysis of continuous data, we grouped the patients into high (>medians) or low (≤medians) groups using the median of each variable, followed by a log-rank test. Variables with a level of significance less than or equal to 0.100 were then included in a multivariate analysis by stepwise Cox regression. Disease-free survival was defined as the time after surgery without any tumor recurrence. Patients were further divided into an early-phase recurrence group with recurrence recorded within 2 years of surgery, and a late-phase group without any recurrence recorded within 2 years of surgery. We defined overall survival as the time from operation till death. Univariate analysis was conducted to screen for potential variables. All statistical calculations were performed using Prism version 8.2.0, GraphPad, La Jolla, CA) and SPSS software (version 25.0.0.2, IBM Corp, Armonk, NY). We considered statistical significance at P < .050.

3. Results

3.1. Analysis of demographics of the study population

EIGHTY nine resected HCC tissue samples were included in the current study. Of the patients, 86.5% were male. The median age of the sampled patients was 52 (18.50) years. Patients had a history of hepatitis B infection (79.8%) and liver cirrhosis (70.8%), which is a typical representative of the eastern population. Twelve patients (13.5%) had multiple tumor lesions as seen in preoperative imaging. Five (5.6%) and 6 (6.7%) patients had microvascular and macrovascular invasions, respectively, as observed in postoperative pathological examination. Of the 89 patients, 50 (56.2%) patients were classified as BCLC stage A, 5 (5.6%), 15 (16.9%), and 19 (21.3%) patients were classified as stage 0, B, and C, respectively. Fifty three patients (59.6%) were beyond the Milan criteria. We have summarized the demographic data in Table 1. The median follow-up after resection was 36.97 months. The estimated cumulative proportion of overall survival at 1, 3, and 5 years was 89.7%, 87.0%, and 81.1%, respectively, and that of disease-free survival was 92.1%, 66.3%, and 34.5%, respectively.
Table 1
Demographics of the study cohort.

| Variables                        | All (n = 89) | With recurrence (n = 73) | Without recurrence (n = 16) | P value |
|----------------------------------|-------------|--------------------------|----------------------------|---------|
| Gender (Male/Female)             | 77 (86.5%)/12 (13.5%) | 63 (86.3%)/10 (13.7%) | 14 (87.5%)/2 (12.5%) | 1.000  |
| Age (Years) (Median (IQR))       | 52.00 (18.50) | 52.00 (18.00)            | 53.00 (24.00)             | .600   |
| HBV (71 (79.8%))                 | 63 (86.3%) | 49 (67.1%) | 14 (87.5%) | .135 |
| Cirrhosis                        | 63 (70.8%) | 49 (67.1%) | 14 (87.5%) | .135 |
| AFP (ng/mL) (Median (IQR))       | 67.00 (874.50) | 80.00 (874.50) | 21.36 (767.50) | .304  |
| Tumor Size (cm) (Median (IQR))   | 5.00 (5.00) | 5.00 (5.00) | 4.50 (3.75) | .348  |
| Tumor Multiplicity               | 12 (13.5%) | 11 (15.1%) | 1 (6.3%) | .686  |
| Microvascular Invasion           | 5 (5.6%) | 5 (6.8%) | 0 (0.0%) | .580  |
| Macrovacular Invasion            | 6 (6.7%) | 6 (6.2%) | 0 (0.0%) | .586  |
| BCLC Stage (0/A/B/C)             | 5 (5.6%)/50 (56.2%) | 5 (6.8%)/37 (50.7%) | 0 (0.0%)/13 (81.3%) | .134  |
| Beyond Milan Criteria            | 53 (59.6%) | 45 (61.6%) | 8 (50.0%) | .412  |
| Albumin (g/L) (Median (IQR))     | 41.00 (5.85) | 41.00 (5.45) | 43.00 (6.75) | .292  |
| ALT (U/L) (Median (IQR))         | 37.00 (39.00) | 38.00 (42.00) | 32.50 (19.25) | .435  |
| AST (U/L) (Median (IQR))         | 37.00 (30.50) | 38.00 (31.00) | 32.50 (12.00) | .318  |
| Bilirubin (µmol/L) (Median (IQR))| 17.00 (8.50) | 17.10 (8.35) | 16.55 (8.80) | .575  |
| WBC (10⁹/L) (Median (IQR))       | 5.37 (2.75) | 5.33 (2.26) | 5.97 (3.90) | .525  |
| HGB (g/L) (Median (IQR))         | 139.00 (23.50) | 140.00 (27.00) | 133.00 (16.75) | .129  |
| PLT (10⁹/L) (Median (IQR))       | 124.00 (86.00) | 124.00 (90.00) | 108.50 (87.25) | .642  |
| CD3 (cells/HPF) (Median (IQR))   | 86.00 (145.83) | 70.67 (123.83) | 166.50 (179.25) | .012  |
| CD8 (cells/HPF) (Median (IQR))   | 35.00 (64.67) | 31.00 (60.67) | 66.00 (88.92) | .062  |
| FoxP3 (cells/HPF) (Median (IQR)) | 11.00 (23.67) | 9.00 (22.33) | 17.50 (26.58) | .323  |
| IMVD (vessels/HPF) (Median (IQR))| 26.67 (22.83) | 26.00 (24.17) | 32.33 (19.58) | .240  |

AFP = serum alpha-fetoprotein, BCLC = barcelona clinic liver cancer, ALT = alanine transaminase, AST = aspartate transaminase, HBV = hepatitis B, IQR = interquartile range, IMVD = intratumoral microvessel density, PLT = platelets, WBC = white blood cells.

Figure 1. Overall (A) and disease-free (B) survival of all patients. Kaplan–Meier curves for overall (time from resection to death) and disease-free (time from resection to recurrence) survival of all patients.
During the follow-up period, 73 (82.0%) patients showed postoperative recurrence, and these recurrent patients had a significantly higher proportion of hepatitis infection (63, 86.3%) in comparison with those patients without recurrence (8, 50.0%, \( P = .003 \)). We did not observe any other significant demographic differences regarding the recurrence. (Table 1) Fifty-four (74.0%) of all recurrent patients had undergone certain treatments; these were, radiofrequency ablation (29 cases, 39.7%), repeat hepatectomy (17 cases, 23.3%), and transarterial chemoembolization (8 cases, 11.0%). Following the BCLC staging, patients were divided into 2 groups (stage 0-A, and stage B-C) for Kaplan–Meier survival analysis. We found that patients with BCLC stage 0-A had a significantly better overall survival (Fig. 2A, \( P = .024 \)) and disease-free survival (Fig. 2B, \( P = .016 \)) than those with stage B-C. Therefore, we considered our cohort to be representative of eastern HCC population with acceptable sample size for further investigation.

### 3.2. Intratumoral microvessel density correlates with tumor-infiltrating leukocytes

Quantification of TILs showed that in our current cohort, the median (IQR) cell density for CD3+, CD8+, and FoxP3+ were 86.00 (145.83) cells/high power field (HPF) (High Power Field, \( 200 \times \)), 35.00 (64.67) cells/HPF, and 11.00 (23.67) cells/HPF, respectively (Fig. 3A). The median (IQR) iMVD was 26.67 (22.83) vessels/HPF (Fig. 3B). We observed a significantly higher number of CD3+ cells in patients without recurrence (166.50 [179.25]) compared with those with recurrence (70.67 [123.83], \( P = .012 \)), as well as a higher tendency for CD8+ cells (66.00 [88.92] vs 31.00 (60.67), \( P = .062 \)). No significant difference was observed in FoxP3+ cells (\( P = .323 \)) and iMVD (\( P = .240 \)) (Table 1). Figure 4 shows representative staining of CD3, CD8, FoxP3, and CD31 on similar location from 1 patient.

Further, correlation analysis showed that the infiltration of CD3+ cells significantly correlated with CD8+ (\( r = 0.560, P < .001 \)) (Fig. 5A) and FoxP3+ cells (\( r = 0.445, P < .001 \)) (Fig. 5B). In addition, infiltration of CD8+ cells was significantly correlated with FoxP3+ cells (\( r = 0.348, P = .001 \)) (Fig. 5C). Due to the fact that CD8+ and FoxP3+ cells (commonly known as Cytotoxic T cells and Regulatory T cells) are 2 major subtypes of CD3+ cells (commonly known as Total T cells), we further obtained a stronger correlation value between the infiltration of CD3+ cells and the summary of CD8+ and FoxP3+ cells (\( r = 0.616, P < .001 \)) (Fig. 5D). Correlation analysis between iMVD and TILs revealed significant correlations between iMVD and CD3+ cells (\( r = 0.338, P = .001 \)) (Fig. 6A) as well as between iMVD and CD8+ cells (\( r = 0.320, P = .002 \)) (Fig. 6B). However, no significant correlation was found between iMVD and FoxP3+ cells (\( r = 0.153, P = .152 \)) (Fig. 6C).

![Figure 3](image-url) The expression analysis of CD3, CD8, FoxP3 (A), and CD31 (B) of all patients. For each case, average number of cells or vessels were calculated from three representative HPFs (high power field). Data for all patients were presented as median (interquartile range).
3.3. Infiltration of CD3+ predicts overall survival

In the analysis of demographic and routine laboratory data, we found that high infiltration of CD3+ cells was significantly related to small tumor size (P = .026), low macrovascular invasion (P = .026), low BCLC stage (P = .009), and low platelet count (P = .040). High infiltration of FoxP3+ cells was significantly related to high serum AFP (P = .005) and high iMVD was significantly related to less macrovascular invasion (P = .012).
Infiltration of CD8+ cells was not significantly related to any variables in the data. (Supplemental Digital Content Table S1, http://links.lww.com/MD/G516)

From the results of Kaplan–Meier analysis, high infiltration of CD3+ ($P<.001$) (Fig. 7A) and CD8+ cells ($P=.015$) (Fig. 7C) predicted better overall survival. Infiltration of FoxP3+ cells ($P=.163$) (Fig. 7E) and iMVD ($P=.362$) (Fig. 7G) had no significant relationship with overall survival. No significant influence on disease-free survival was found regarding infiltration of CD3+ ($P=.386$) (Fig. 7B), CD8+ ($P=.648$) (Fig. 7D), FoxP3+ cells ($P=.708$) (Fig. 7F), and iMVD ($P=.939$) (Fig. 7H).

In addition, we performed univariate Kaplan–Meier analysis for all demographic variables, and found that BCLC stage ($P=.024$), albumin ($P=.048$), and tendencies for bilirubin ($P=.062$) significantly predicted overall survival. (Table 2) These variables along with CD3+ and CD8+ cells were then included for multivariate Cox regression analysis. After the multivariate statistical analysis, only CD3+ cells remained an independent predictor for overall survival. (Table 3)

Furthermore, hepatitis B ($P=.013$), AFP ($P=.045$), microvascular ($P=.024$) and macrovascular ($P=.029$) invasions, BCLC stage ($P=.016$), and ALT ($P=.026$) were significant predictors

![Figure 5. Correlations among CD3, CD8, and FoxP3. Correlations were assessed by calculating Pearson’s $r$ values.](image)

![Figure 6. Correlation between iMVD and CD3 (A), CD8 (B), and FoxP3 (C). Correlations were assessed by calculating Pearson’s $r$ values.](image)
for disease-free survival in univariate analyses. (Table 2) Cox regression analysis showed that hepatitis B ($P = .023$), AFP ($P = .025$), microvascular invasion ($P = .010$), and ALT ($P = .009$) were independent predictive values for disease-free survival. (Table 4)

### 3.4. Infiltration of CD3+ predicts late-phase disease-free survival

We further separated all patients into early-phase (recurrence recorded within 2 years of resection, $n=64$) and late-phase groups (without recurrence recorded within 2 years of resection

![Kaplan-Meier curves of infiltration of CD3+ (A, B), CD8+ (C, D), FoxP3+ (E, F) cells, and IMVD (G, H) for overall and disease-free survival. For Kaplan-Meier analysis, patients were grouped as high (red curve) or low (blue curve), according to medians. Log-rank test was used to compare significance.](image-url)
and patients with no recurrence, n = 25). We performed Kaplan–Meier estimate on these 2 groups comparing high or low infiltration of TILs and iMVD. The infiltration of CD3+ (P = .586) (Fig. 8A), CD8+ (P = .178) (Fig. 8B), FoxP3+ cells (P = .152) (Fig. 8C), and iMVD (P = .509) (Fig. 8D) had no significant influence on early-phase disease-free survival. The high infiltration of CD3+ (P = .014) (Fig. 9A) and CD8+ cells (P = .035) (Fig. 9B) significantly predicted better late-phase disease-free survival, but infiltration of FoxP3+ cells (P = .978) (Fig. 9C) and iMVD (P = .550) (Fig. 9D) could not significantly predict late-phase disease-free survival.

Univariate analyses showed no significant demographic variables for predicting early-phase disease-free survival, except for a tendency from white blood cell count (P = .072). (Table 5)

For late-phase disease-free survival, tumor size (P = .076) and albumin (P = .056) showed potential predictabilities and were included in multivariate analysis with CD3+ (P = .014) and CD8+

### Table 2

| Variables                  | Overall survival (P values) | Disease-free survival (P values) |
|----------------------------|-----------------------------|---------------------------------|
| Gender                     | .512                        | .804                            |
| Age                        | .240                        | .301                            |
| HBV                        | .922                        | .013                            |
| Cirrhosis                  | .826                        | .270                            |
| AFP                        | .472                        | .045                            |
| Tumor size                 | .144                        | .503                            |
| Tumor multiplicity         | .552                        | .262                            |
| Microvascular invasion     | .103                        | .024                            |
| Macrrovascular invasion    | .147                        | .029                            |
| BCLC stage                 | .024                        | .016                            |
| Beyond milan criteria      | .190                        | .305                            |
| Albumin                    | .048                        | .239                            |
| ALT                        | .420                        | .026                            |
| AST                        | .135                        | .409                            |
| Bilirubin                  | .062                        | .693                            |
| WBC                        | .380                        | .971                            |
| HGB                        | .443                        | .309                            |
| PLT                        | .248                        | .467                            |
| CD3+ cells                 | .001                        | .386                            |
| CD8+ cells                 | .015                        | .648                            |
| FoxP3+ cells               | .163                        | .708                            |
| iMVD                       | .362                        | .939                            |

### Table 3

| Variable                  | Hazard ratio | 95% Confidence interval | P value |
|---------------------------|--------------|-------------------------|---------|
| CD3                       | 0.012        | 0.001-0.789             | .038    |

### Table 4

| Variable                  | Hazard ratio | 95% Confidence interval | P value |
|---------------------------|--------------|-------------------------|---------|
| HBV                       | 2.200        | 1.113-4.349             | .023    |
| AFP                       | 1.740        | 1.074-2.818             | .025    |

**AFP = serum alpha-fetoprotein, ALT = alanine transaminase, AST = aspartate transaminase, BCLC = barcelona clinic liver cancer, HGB = hemoglobin, HBV = hepatitis B, iMVD = intratumoral microvessel density, PLT = platelets, WBC = white blood cells.**

For Kaplan–Meier analysis, patients were grouped as high (red curve) or low (blue curve), according to medians. Log-rank test was used to compare significance.

**Figure 8.** Kaplan–Meier curves of infiltration of CD3+ (A), CD8+ (B), FoxP3+ (C), and iMVD (D) for early-phase disease-free survival. For Kaplan–Meier analysis, patients were grouped as high (red curve) or low (blue curve), according to medians. Log-rank test was used to compare significance.
After the multivariate process, CD3+ (P = .012), tumor size (P = .032) and albumin (P = .007) were independent predictors for late-phase disease-free survival.

Table 5
Univariate Kaplan–Meier analysis on early- and late-phase DFS.

| Variables          | Early-phase DFS (P values) | Late-phase DFS (P values) |
|--------------------|----------------------------|---------------------------|
| Gender             | .436                       | .986                      |
| Age                | .287                       | .963                      |
| HBV                | .588                       | .258                      |
| Cirrhosis          | .267                       | .107                      |
| AFP                | .196                       | .837                      |
| Tumor size         | .672                       | .076                      |
| Tumor multiplicity | .340                       | .760                      |
| Microvascular invasion | 243                     | n.a.                      |
| Macrovacular invasion | 329                     | n.a.                      |
| BCLC stage         | .649                       | .285                      |
| Beyond milan criteria | .776                     | .255                      |
| albumin            | .493                       | .056                      |
| ALT                | .299                       | .187                      |
| AST                | .832                       | .245                      |
| Bilirubin          | .612                       | .129                      |
| WBC                | .072                       | .407                      |
| HGB                | .336                       | .166                      |
| PLT                | .688                       | .526                      |
| CD3+ cells         | .586                       | .014                      |
| CD8+ cells         | .178                       | .035                      |
| FoxP3+ cells       | .152                       | .978                      |
| iMVD               | .509                       | .550                      |

Table 6
Multivariate Cox regression of included variables on late-phase DFS.

| Variables          | Hazard ratio | 95% Confidence interval          | P values |
|--------------------|--------------|----------------------------------|----------|
| CD3                | 0.036        | 0.003–0.481                      | .012     |
| Tumor size         | 12.658       | 1.247–125.00                     | .032     |
| Albumin            | 0.018        | 0.001–0.336                      | .007     |

Figure 9. Kaplan–Meier curves of infiltration of CD3+ (A), CD8+ (B), FoxP3+ (C), and iMVD (D) for late-phase disease-free survival. For Kaplan–Meier analysis, patients were grouped as high (red curve) or low (blue curve), according to medians. Log-rank test was used to compare significance.

4. Discussion
In this study, we found a correlation between iMVD and infiltration of CD3+ and CD8+ cells. We also confirmed the significant predictability of infiltration of CD3+ cells on the overall and late-phase disease-free survival after resection of HCC.

Many previous studies have suggested that the high intra-tumoral infiltration of CD3+ and CD8+ cells could better predict overall or disease-free survival.[17–20] In the present study, we confirmed the influence of CD3+ and CD8+ cell infiltration on overall survival, but failed to prove their influence on disease-free survival. However, we noticed high recurrence rate within 2 years of resection in the current cohort. Since 2 years has been widely considered as a cut-off point for distinct mechanisms (metastasis or de novo) of intrahepatic recurrence after resection of HCC,[21]
we separated patients into early and late-phase disease-free survival groups, and found that high infiltration of CD3+ and CD8+ cells correlated with better late-phase disease-free survival, but not early-phase. A possible explanation for this could be that a major antitumor effect of the infiltrating CD3+ and CD8+ cells is preventing carcinogenesis rather than clearing existing cancer cells. Due to the high interaction effects between CD3+ and CD8+ cells, after multivariate analyses, CD8+ cells was excluded and CD3+ cells remained as independent predictors for overall and late-phase disease-free survival. Meanwhile, in our cohort, we also validated the independent predictabilities for disease-free survival from the well-known clinical variables for tumor aggressiveness including AFP, microvascular invasion, and tumor size, and those variables for impaired liver function including hepatitis B, ALT, and albumin.

In our results, we failed to obtain a significant predictability for the infiltration of FoxP3+ cells on disease-free or overall survival. Previous publications have indicated that high infiltration of FoxP3+ cells could predict worse overall and disease-free survival.\(^{12-26}\) In contrast, there are several studies that failed to validate the influence of FoxP3+ cells on survival.\(^{27,28}\) In this study, the number of FoxP3 expressed cells was notably lower than that of CD8, and was considerably correlated with CD8. Therefore, we infer that in our study most cases were predominantly CD8+ infiltrated, and the pro-tumor effect from FoxP3+ cells is mainly due to the suppression of immune effector cells. Hence, it could not be observed statistically in our study.

In our previous study on a western HCC cohort, we noticed that intratumoral CD3+, CD8+, CD20+, and CD66b+ cells were present predominately around the intratumoral microvessels.\(^{14}\) We used perivascular regions to capture the hotspots for further survival analysis and validated the prognostic significance.\(^{14}\) However, it was too weak to prove a relationship between immune cell infiltration and neovascularization, which we were unable to quantify. In this study, we quantified neovascularization by measuring iMVD using the well-known Weidner’s method. We proved that iMVD significantly correlated with TILs in clinical HCC tissue. This correlation is similar to that in other human solid tumors.\(^{8,29,30}\) Therefore, we suggest that neovascularization in HCC could be protective by promoting immune effector cell infiltration, which is dependent on the network of blood vessels. We further assume that for patients who possibly had high immune effector cell infiltration, the outcome of angiogenesis-targeted therapies, such as transarterial chemoembolization, sorafenib, regorafenib, and lenvatinib, may not be satisfactory.

Previous animal studies have revealed that Tregs could contribute to neovascularization through several mechanisms, including suppression of effector T cells and induction of chemokine CCL28 expression.\(^{9,31}\) In a previous clinical study, the author also observed a positive correlation between tumor-infiltrating Tregs and microvessel density in HCC.\(^{12}\) However, in our clinical HCC cohort, we could not validate the association between FoxP3+ cells and iMVD. The correlation between Tregs and microvessel density might have resulted from the probable interaction between them, where microvessels bring more T cells comprising Tregs into the tumor, and Tregs in turn promotes angiogenesis by the mechanisms mentioned above. In our study, we have provided evidence for the following: (a) iMVD correlated with high CD3+ cells, (b) CD3+ cells showed correlation with FoxP3+ cells, and (c) the direct significance of FoxP3+ cells and iMVD was not observed when the major subtype of T cells, CD8+ cells, were excluded.

The limitations of the current study were the relatively small sample size and one-point sampling without considering intratumoral heterogeneity, which might have resulted in the lack of statistical robustness.

5. Conclusion
In conclusion, our data suggests that increased iMVD could enrich more tumor-infiltrating CD3+ cells. Infiltrated CD3+ cells could help to better predict both the overall and late-phase disease-free survival after resection of HCC.

Author contributions
Acquisition of data: Yuan Yang, Haiqing Wang.
Analysis and interpretation of data: Yuan Yang, Ning Fu, Jingcheng Hao.
Conceptualization and methodology: Yuan Yang, Ning Fu, Jingcheng Hao.
Development of methodology: Yuan Yan, Jingcheng Hao.
Funding Acquisition: Yuan Yang, Jingcheng Hao.
Writing, review and/or revision of the manuscript: Yuan Yang, Ning Fu, Haiqing Wang, Jingcheng Hao.

References
[1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108.
[2] Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–17.
[3] Sachdeva M, Chawla YK, Arora SK. Immunology of hepatocellular carcinoma. World J Hepatol 2015;7:2080–90.
[4] Karakhanova S, Ryschies I, Mosl B, et al. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. Br J Cancer 2015;112:1027–36.
[5] Sun C, Xu J, Song J, et al. The predictive value of centre tumour CD8(+) T cells in patients with hepatocellular carcinoma: comparison with Immunoscoring. Oncotarget 2015;6:35602–15.
[6] Anitei MG, Zeitoun G, Mlecnik B, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 2014;20:1891–9.
[7] Matsui O. Imaging of multistep human hepatocarcinogenesis by CT during intra-arterial contrast injection. Intervirology 2004;47:271–6.
[8] Martinet L, Garrido I, Filleron T, et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res 2011;71:5678–87.
[9] Facciaebene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012;72:2162–71.
[10] Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer 2018;7:355–60.
[11] Qin S, Primary Liver Cancer D. Treatment expert panel of the Chinese ministry of H. Guidelines on the diagnosis and treatment of primary liver cancer (2011 edition). Chin Clin Oncol 2012;1:10.
[12] Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301–14.
[13] Mazzafuero V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–9.
[14] Schoenbergen MB, Hao J, Bucher JN, et al. Perivascular tumor-infiltrating leukocyte scoring for prognosis of resected hepatocellular carcinoma patients. Cancers (Basel) 2018;10:10.
[15] Miksch RC, Hao J, Schoenbergen MB, et al. Development of a reliable and accurate algorithm to quantify the tumor immune stroma (QTiS) across tumor types. Oncotarget 2017;8:114935–44.
[16] Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995;36:169–80.

[17] Cai XY, Gao Q, Qu SJ, et al. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol 2006;132:293–301.

[18] Gabrielson A, Wu Y, Wang H, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res 2016;4:419–30.

[19] Garnelo M, Tan A, Her Z, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut 2017;66:342–51.

[20] Unitt E, Marshall A, Gelson W, et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 2006;45:246–53.

[21] Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200–7.

[22] Kobayashi N, Hiraoka N, Yamagami W, et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007;13:902–11.

[23] Gao Q, Qu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586–93.

[24] Sasaki A, Tanaka F, Mimori K, et al. Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol 2008;34:173–9.

[25] Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer 2009;125:1640–8.

[26] Wu Y, Kuang DM, Pan WD, et al. Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. Hepatology 2013;57:1107–16.

[27] Shen X, Li N, Li H, Zhang T, Wang F, Li Q. Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma. J Cancer Res Clin Oncol 2010;136:1745–54.

[28] Yang ZQ, Yang ZY, Zhang LD, et al. Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients. Human Immunol 2010;71:1180–8.

[29] Giatromanolaki A, Bates GJ, Koukourakis MI, et al. The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol Oncol 2008;109:216–21.

[30] Gupta S, Joshi K, Wig JD, Arora SK. Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis. Acta Oncol 2007;46:792–7.

[31] Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature 2011;475:226–30.

[32] Huang Y, Wang FM, Wang T, et al. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients. Digestion 2012;86:329–37.